LC8A Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Calliditas Therapeutics AB

Watchlist Manager

Watchlist

Price: 35 EUR -1.13%

Market Cap: €945.6m

	Calliditas Therapeutics AB F:LC8A	SE
B	Borussia Dortmund GmbH & Co KGaA PSE:BVB	DE
R	Restaurant Brands New Zealand Ltd OTC:RTBRF	NZ
	Bong AB F:20L	SE
T	Treatt PLC F:5TT	UK

Profitability Summary

Calliditas Therapeutics AB's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

93%

Strong 3Y Average Gross Margin

95%

Declining Gross Margin

97% > 93%

Negative Operating Margin

-22%

Negative 3Y Average Operating Margin

-29%

Operating Margin is Increasing

-23% > -22%

Negative Net Margin

-30%

Negative 3Y Average Net Margin

-37%

Declining Net Margin

-25% > -30%

Negative Free Cash Flow Margin

-15%

Negative 3Y Average Free Cash Flow Margin

-26%

Free Cash Flow Margin is Increasing

-25% > -15%

Negative ROE

-157%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-55%

Declining ROIC

-41% > -46%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.